Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Goldsmith

Showing results (21-30 of 73) with videos related to

Pageof 8
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 23, 2016
Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future DirectionsBrian J Miller, David R Goldsmith
The Primary Care Companion for CNS Disorders|December 15, 2018
Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be RiskyMina Boazak, David R Goldsmith, Robert O Cotes
Brain, Behavior, and Immunity|August 22, 2023
Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: A meta-regression and critical commentaryAnjali Chandra, Brian J Miller, David R Goldsmith
Community Mental Health Journal|November 10, 2022
Antipsychotics and Medical Comorbidity: A Retrospective Study in an Urban Outpatient Psychiatry ClinicCatherine W Bennett, Lauren Gensler, David R Goldsmith
Case Reports in Psychiatry|February 25, 2026
Managing Recurrent Postictal Worsening of Psychosis in Clozapine-Treated Schizophrenia: A Case ReportRafae Alam, Robert O Cotes, David R Goldsmith
Frontiers in Integrative Neuroscience|February 10, 2022
Clinical and Structural Differences in Delusions Across Diagnoses: A Systematic ReviewKelly Rootes-Murdy, David R Goldsmith, Jessica A Turner
Frontiers in Psychiatry|November 11, 2020
Selective Review of Neuroimaging Findings in Youth at Clinical High Risk for Psychosis: On the Path to Biomarkers for ConversionJustin K Ellis, Elaine F Walker, David R Goldsmith
Brain, Behavior, and Immunity|June 7, 2019
Psychosis as an adverse effect of monoclonal antibody immunotherapyNorah Essali, David R Goldsmith, Laura Carbone, et al.
Brain, Behavior, and Immunity|November 22, 2019
Reply to the Letter to the Editor: Reduced neuropsychiatric events as "beneficial reactions" to drugs: Seek associations with cautionNorah Essali, David R Goldsmith, Laura Carbone, et al.
CNS Drugs|January 21, 2004
Spotlight on lamotrigine in bipolar disorderDavid R Goldsmith, Antona J Wagstaff, Tim Ibbotson, et al.
Pageof 8

Showing results (21-30 of 73) with videos related to

Sort By:
Pageof 8
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 23, 2016
Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future DirectionsBrian J Miller, David R Goldsmith
The Primary Care Companion for CNS Disorders|December 15, 2018
Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be RiskyMina Boazak, David R Goldsmith, Robert O Cotes
Brain, Behavior, and Immunity|August 22, 2023
Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: A meta-regression and critical commentaryAnjali Chandra, Brian J Miller, David R Goldsmith
Community Mental Health Journal|November 10, 2022
Antipsychotics and Medical Comorbidity: A Retrospective Study in an Urban Outpatient Psychiatry ClinicCatherine W Bennett, Lauren Gensler, David R Goldsmith
Case Reports in Psychiatry|February 25, 2026
Managing Recurrent Postictal Worsening of Psychosis in Clozapine-Treated Schizophrenia: A Case ReportRafae Alam, Robert O Cotes, David R Goldsmith
Frontiers in Integrative Neuroscience|February 10, 2022
Clinical and Structural Differences in Delusions Across Diagnoses: A Systematic ReviewKelly Rootes-Murdy, David R Goldsmith, Jessica A Turner
Frontiers in Psychiatry|November 11, 2020
Selective Review of Neuroimaging Findings in Youth at Clinical High Risk for Psychosis: On the Path to Biomarkers for ConversionJustin K Ellis, Elaine F Walker, David R Goldsmith
Brain, Behavior, and Immunity|June 7, 2019
Psychosis as an adverse effect of monoclonal antibody immunotherapyNorah Essali, David R Goldsmith, Laura Carbone, et al.
Brain, Behavior, and Immunity|November 22, 2019
Reply to the Letter to the Editor: Reduced neuropsychiatric events as "beneficial reactions" to drugs: Seek associations with cautionNorah Essali, David R Goldsmith, Laura Carbone, et al.
CNS Drugs|January 21, 2004
Spotlight on lamotrigine in bipolar disorderDavid R Goldsmith, Antona J Wagstaff, Tim Ibbotson, et al.
Pageof 8